Afuco™ Anti-CD33 ADCC Recombinant Antibody (Lintuzumab), ADCC Enhanced (CAT#: AFC-TAB-756)

• Excellent for Studying Cancer Cells
  Lintuzumab has been transformative for our research on CD33-positive cancer cells. Its enhanced ADCC capability has allowed us to study immune responses more effectively, laying the groundwork for potential new therapies.
• High Specificity
  Lintuzumab consistently demonstrates high specificity for CD33, with minimal off-target effects. This specificity ensures our results are accurate, making it indispensable for our CD33-positive cancer research.
• Robust Functional Analysis
  The data we've gained from using Lintuzumab in functional assays has been robust and reliable. It has played a crucial role in understanding ADCC dynamics and the therapeutic targeting of CD33-positive cells.

1. Q 1: How should lintuzumab be stored to maintain its effectiveness?

   A: To ensure Lintuzumab remains effective, store it at -20°C or lower. Aliquot it upon first use to avoid repeated thawing and refreezing, which can degrade its efficacy over time.

2. Q 2: How can I figure out how much lintuzumab is best for my experiments?

   A: Perform a titration by testing a range of concentrations, typically from 0.1 μg/ml to 10 μg/ml. This helps identify the concentration that provides effective binding and ADCC activity in your specific experimental conditions.

3. Q 3: Is it possible to investigate whether ADCC effectively eliminates cancer cells using linduzumab?

   A: Yes, Lintuzumab is designed to enhance ADCC. You can use it in assays that measure natural killer cell activity to assess how effectively it promotes the destruction of CD33-positive cancer cells.

View the frequently asked questions answered by Creative Biolabs Support.